TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase Ib/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which has completed a Phase I/II study in acute myocardial infarction. The company has operations in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium. As of July 3, 2018, TiGenix NV operates as a subsidiary of Takeda Pharmaceutical Company Limited.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-639-6060
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
TIGENIX/S (NASDAQ:TIG) Frequently Asked Questions
What is TIGENIX/S's stock symbol?
TIGENIX/S trades on the NASDAQ under the ticker symbol "TIG."
Has TIGENIX/S been receiving favorable news coverage?
News articles about TIG stock have trended somewhat positive this week, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TIGENIX/S earned a news impact score of 1.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of TIGENIX/S's key competitors?
Some companies that are related to TIGENIX/S include Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Impax Laboratories (IPXL), Juniper Pharmaceuticals (JNP), Oncolytics Biotech (ONCYF), Orexigen Therapeutics (OREX), Rosetta Genomics (ROSG), Steadymed (STDY) and TapImmune (TPIV).
What other stocks do shareholders of TIGENIX/S own?
Who are TIGENIX/S's key executives?
TIGENIX/S's management team includes the folowing people:
- Dr. Claudia D'Augusta, Chief Financial Officer and Compliance Officer (Age 48)
- Mr. Wilfried Dalemans, Chief Technical Officer (Age 60)
- Claudia Jiménez, Sr. Director of Investor Relations & Communications
- An Moonen, Gen. Counsel and Company Sec.
- Dr. Marie Paule Richard, Chief Medical Officer (Age 63)
When did TIGENIX/S IPO?
(TIG) raised $26 million in an initial public offering on Thursday, December 15th 2016. The company issued 2,800,000 shares at $9.12 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of TIGENIX/S?
Shares of TIG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TIGENIX/S's official website?
How can I contact TIGENIX/S?
TIGENIX/S's mailing address is ROMEINSE STRAAT 12 BOX 2 3001, LEUVEN C9, 3001. The company can be reached via phone at 321-639-6060 or via email at [email protected]
MarketBeat Community Rating for TIGENIX/S (NASDAQ TIG)
MarketBeat's community ratings are surveys of what our community members think about TIGENIX/S and other stocks. Vote "Outperform" if you believe TIG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TIG will underperform the S&P 500 over the long term. You may vote once every thirty days.
